ClinicalTrials.gg
Active, not recruitingNCT04372953POLARUpdated Feb 19, 2026

Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial).

An interventional study of Positive End-Expiratory Pressure (PEEP) in Lung Injury and Preterm Birth, sponsored by Murdoch Childrens Research Institute. Active, not recruiting at 27 sites in 7 countries. Open to participants aged 23 Weeks to 28 Weeks. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Murdoch Childrens Research Institute · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
906
Allocation
Randomized
Ages
23 Weeks to 28 Weeks
Sex
All
01

Study summary

Premature babies often need help immediately after birth to open their lungs to air, start breathing and keep their hearts beating. Opening their lungs can be difficult, and once open the under-developed lungs of premature babies will often collapse again between each breath. To prevent this nearly all premature babies receive some form of mechanical respiratory support to aid breathing. Common to all types of respiratory support is the delivery of a treatment called positive end-expiratory pressure, or PEEP. PEEP gives air, or a mixture of air and oxygen, to the lung between each breath to keep the lungs open and stop them collapsing.

Currently, clinicians do not have enough evidence on the right amount, or level, of PEEP to give at birth. As a result, doctors around the world give different amounts (or levels) of PEEP to premature babies at birth.

In this study, the Investigators will look at 2 different approaches to PEEP to help premature babies during their first breaths at birth. At the moment, the Investigators do not know if one is better than the other. One is to give the same PEEP level to the lungs. The others is to give a high PEEP level at birth when the lungs are hardest to open and then decrease the PEEP later once the lungs are opened and the baby is breathing.

Very premature babies have a risk of long-term lung disease (chronic lung disease). The more breathing support a premature baby needs, the more likely the risk of developing chronic lung disease. The Investigators want to find out whether one method of opening the baby's lungs at birth results in them needing less breathing support.

This research has been initiated by a group of doctors from Australia, the Netherlands and the USA, all who look after premature babies.

Read the detailed description

All infants born \<29 weeks' postmenstrual age (PMA) require positive end-expiratory pressure (PEEP) at birth. PEEP is a simple, feasible and cost-effective therapy to support extremely preterm infants that is used globally. The effective and safe level of PEEP to use after preterm birth remains the most important unanswered question in neonatal respiratory medicine.

The Investigators will undertake an international multi-centre randomised controlled trial to address in extremely preterm infants, whether the use of a high, dynamic PEEP level strategy to support the lung during stabilisation ('resuscitation') at birth, compared to the current practice of a static PEEP level, will reduce the rate of death or bronchopulmonary dysplasia (BPD).

This trial will address the following four key knowledge gaps:

  1. Assessing whether individualising (dynamic) PEEP is superior to static PEEP
  2. The uncertainty regarding applied pressure strategies to support the lung during stabilisation at birth arising from the lack of a properly powered, well-designed randomised trial specifically addressing important outcomes for respiratory support in the Delivery Room
  3. The optimal PEEP strategy to use
  4. Determining the differential effects of PEEP at different gestational ages.

For this study, the term PEEP refers to the delivery of positive pressure (via a bias flow of gas) to the lungs during expiration by any method of assisted respiratory support, this includes:

  1. Continuous Positive Applied Pressure (CPAP; a method of non-invasive respiratory support). During CPAP no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort. PEEP during CPAP has also been called 'continuous distending pressure.
  2. Positive Pressure Ventilation (PPV). During PPV PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV).
  3. High-frequency oscillatory ventilation (HFOV) or high-frequency jet ventilation. These are modes of invasive PPV in which PIP is delivered at very fast rates (>120 inflations per minute) and at very small tidal volumes. During HFOV a mean airway pressure is determined by the clinician which is equivalent to the PEEP during other modes. During high-frequency jet ventilation the clinician sets a PEEP similar to CMV.

As all of these modes of ventilation have a similar goal of applying a pressure to the lung during expiration (usually to prevent lung collapse) the term PEEP has the same physiological result despite different methods of application.

The specific aim of the trial is to establish whether the use of a high, dynamic 8-12 cmH2O PEEP level ('dynamic') strategy to support the lung during stabilisation at birth, compared with a static 5-6 cmH2O PEEP level ('static') strategy, increases the rate of survival without bronchopulmonary dysplasia (BPD) in extremely preterm infants born \<29 weeks' PMA, and reduces rates of common neonatal morbidities.

The Investigators hypothesise that in preterm infants born \<29 weeks PMA who receive respiratory support during stabilisation at birth, a high, dynamic PEEP strategy (i.e. PEEP 8-12 cmH2O individualised to clinical need) as compared to a standard, static PEEP of 5-6 cmH2O, will:

  1. Increase survival without BPD (primary outcome); and
  2. Reduce rates of common neonatal morbidities such as failure of non-invasive respiratory support in the first 72 hours of life (secondary outcome).

This trial is a phase III/IV, two parallel group, non-blinded, 1:1 randomised controlled, multi-national, multi-centre study comparing dynamic PEEP (dynamic group) with standard PEEP strategy (static group).

The intervention will take place in the Delivery Room. The intervention period will be from the time of birth until 20 minutes of life or transfer from Delivery Room to NICU (whatever comes first). The follow-up period will extend to 36 weeks PMA (primary endpoint), and 24 months corrected GA to determine important long-term neurodevelopmental and respiratory outcomes.

The clinical team within the Delivery Room managing enrolled and randomised infants will not be masked/blinded to the intervention. Clinicians need to be able to see the PEEP delivery device to assess efficacy of pressure delivery. The Research Coordinator/Study team at site will also not be masked/blinded to the intervention, as they will be entering trial data into the data management system.

Research staff based at the central Trial Coordinating Centre (TCC), the Data Coordinating Centre (DCCe) and the trial statistician will be blinded to assigned treatment.

There will be a total of 906 infants recruited (453 in the Dynamic group, 453 in the Static group), over 25 recruitment centres across Australia, Europe, the United Kingdom, the Middle East, Canada and North America.

The study will have Regional Coordinating Centres (RCCs) established in the following jurisdictions:

  1. Australia - The Murdoch Children's Research Institute/Royal Women's Hospital, Melbourne, AUS
  2. The Netherlands - Amsterdam University Medical Centre, Netherlands, EU
  3. The United Kingdom - The University of Oxford / National Perinatal Epidemiology Unit (NPEU), Oxford, UK, and
  4. North America - the Hospital of the University of Pennsylvania, Pennsylvania, USA.
02

Conditions studied

  • Lung Injury
  • Preterm Birth

Keywords

  • Resuscitation
  • Positive End-Expiratory Pressure (PEEP)
  • Bronchopulmonary Dysplasia
03

In context

Lung Injury

114 studies on the registry are indexed under Lung Injury; 33 are open to participants now.

This study's planned enrollment of 906 is above the median of 62 across 75 interventional studies indexed under Lung Injury.

Browse Lung Injury studies →

Lead sponsor

Murdoch Childrens Research Institute is the lead sponsor of 99 studies on the registry; 34 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
23 Weeks to 28 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born between 23 weeks 0 days and 28 weeks 6 days PMA (by best obstetric estimate).
  • Receives respiratory intervention (resuscitation) at birth with CPAP and/or positive pressure ventilation in the Delivery Room, to support transition and/or respiratory failure related to prematurity.
  • Has a parent or other legally acceptable representative capable of understanding the document and providing consent on the participant's behalf either prospectively or after birth and randomisation if prenatal consent was not possible (at sites where the Ethics Committee permits waiver of prospective consent).

Exclusion criteria

Exclusion Criteria:

  • Not for active care based on assessment of the attending clinician or family decision
  • Anticipated severe pulmonary hypoplasia due to rupture of membranes \<22 weeks with anhydramnios or fetal hydrops
  • Major congenital anomaly or anticipated alternative cause for respiratory failure
  • Refusal of by their legally acceptable representative
  • Does not have a guardian who can provide informed consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
906 participants (estimated)

Study arms

  • Active comparator
    Static PEEP Group

    Delivery of PEEP at 5-6 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). FiO2 and other aspects of respiratory care are then titrated using a standardised resuscitation algorithm.

    Procedure: Positive End-Expiratory Pressure (PEEP)

  • Experimental
    Dynamic PEEP Group

    Dynamic delivery of PEEP at 8 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). PEEP levels increased step-wise to 10 and/or 12 cmH2O if FiO2/respiratory care needs to be escalated as per a standardised resuscitation algorithm. If an infant shows evidence of respiratory improvement during resuscitative care, PEEP will be reduced in a stepwise method by 2 cmH2O each reduction, but to no lower than 8 cmH2O.

    Procedure: Positive End-Expiratory Pressure (PEEP)

Interventions

  • ProcedurePositive End-Expiratory Pressure (PEEP)

    PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of: 1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort. 2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV).

06

What researchers measure

Primary outcomes

  1. The prevalence of the composite outcome of either death or bronchopulmonary dysplasia (BPD), as assessed by standard oxygen reduction test.

    This is defined as the proportion of participants in the analysis set with a confirmed death date or a diagnosis of bronchopulmonary dysplasia (BPD), at 36 weeks post menstrual age.

    Time frame: At 36 weeks post menstrual age.

Secondary outcomes

  1. The rate/incidence of failure of non-invasive ventilation in first 72 hours, as assessed by intubation status.

    This is defined as the proportion of participants in the analysis set requiring invasive ventilation (i.e. insertion of a Endotracheal Tube (ETT) within the first 72 hours after birth.

    Time frame: From the time of birth until 72 hours post birth.

  2. The rate/incidence of death within the first 10 days of life, as assessed by date of death.

    This is defined as the proportion of participants in the analysis set having dies within the first 10 days post birth.

    Time frame: From the time of birth until 10 days post birth.

  3. Oxygen requirement ≥50% for 3 or more consecutive hours in first 72 hours

    This is defined as highest FiO2 applied for 3 or more consecutive hours in the first 72 hours of age.

    Time frame: From the time of birth until 72 hours post birth.

  4. Supplementary oxygen use

    This is defined as highest FiO2 in the delivery room, and then at 24 hours, 72 hours, 7 days and 10 days of age.

    Time frame: From the time of birth until 10 days of age.

  5. The rate/incidence of surfactant therapy requirement within the first 72 hours of life, as assessed by surfactant therapy status.

    This is defined as the proportion of participants in the analysis set requiring surfactant therapy within the first 72 hours post birth.

    Time frame: From the time of birth until 72 hours post birth.

  6. The rate/incidence of grade 3 and 4 intraventricular haemorrhage within the first 72 hours of life, as defined via imaging.

    This is defined as the proportion of participants in the analysis set requiring experiencing a grade 3 or 4 intraventricular haemorrhage, within the first 72 hours post birth.

    Time frame: From the time of birth until 72 hours post birth.

  7. The rate/incidence of treatment failure within the delivery room, as assessed by intubation status.

    This is defined as the proportion of participants in the analysis set requiring intubation (i.e. insertion of a Endotracheal Tube (ETT) within the delivery room, but prior to transfer to NICU.

    Time frame: From the time of birth through transfer to NICU (within two hours from birth)

  8. The grade of bronchopulmonary dysplasia (BPD), based on the results of an oxygen reduction test.

    This is defined as the grade bronchopulmonary dysplasia (BPD) assigned according to the results of an oxygen reduction test and mode or respiratory support at 36 weeks PMA (see Jensen et al Am J Resp Crit Care Med 2019;200:751-759).

    Time frame: At 36 weeks post menstrual age.

  9. Incidence of Death at 36 week PMA

    This is defined as death at 36 weeks PMA (individual component of primary outcome)

    Time frame: At 36 weeks post menstrual age.

  10. Incidence of Bronchopulmonary dysplasia (BPD) at 36 week PMA

    This is defined as the incidence of BPD at 36 weeks PMA (individual component of primary outcome)

    Time frame: At 36 weeks post menstrual age.

  11. Incidence of air leak and/or pulmonary interstitial emphysema (defined on chest radiograph; CXR) in the first 10 days after birth

    Any airleak, defined as Pneumothorax, pulmonary interstitial emphysema and/or pneumomediastimum, diagnosed by chest radiology within the first 10 days after birth.

    Time frame: Birth to 10 days of age.

  12. Airleak

    Any airleak, defined as Pneumothorax, pulmonary interstitial emphysema and/or pneumomediastimum, diagnosed by chest radiology. Airleak will be coded as occurring in the delivery room, in first 10 days of life, during hospital stay and if requiring drainage (e.g. via a chest tube)

    Time frame: During hospital stay, on average until 36 weeks PMA.

  13. Retinopathy of prematurity (stage 3 or higher or requiring treatment)

    Defined as retinopathy of prematurity (stage 3 or higher or requiring treatment) diagnosed by ophthalmological examination at or before 36-week corrected PMA

    Time frame: 36-week corrected PMA.

  14. Significant brain injury (IVH grade 3 or 4, periventricular leukomalacia)

    Significant brain injury (IVH grade 3 or 4, periventricular leukomalacia) at or before 36-week corrected PMA as assessed by ultrasound or MRI cranial imaging.

    Time frame: 36-week corrected PMA.

  15. Invasive ventilation at day 10 of age

    The rates of invasive ventilation (placement of an endotracheal tube for \>4 hours) by day 7 and 10 of age

    Time frame: First 10 days after birth.

  16. Highest PEEP used during non-invasive ventilation

    Defined as the highest PEEP used during non-invasive ventilation in the NICU (after delivery room management) at 24 hours, 72 hours, 7 and 10 days of age.

    Time frame: Birth to 10 days of age.

  17. Duration of respiratory support

    Defined as the total number of days of all forms of respiratory support (supplementary oxygen therapy, non-invasive and invasive ventilation)

    Time frame: 36 week PMA.

  18. Postnatal steroid use

    Defined as the incidence of one or more course of postnatal steroids for the treatment of BPD

    Time frame: 36 week PMA.

  19. Inotrope use

    Defined as the incidence of the administration of one or more inotropic agent by continuous infusion (not as a resuscitative agent) for more than 1 hour.

    Time frame: 36 week PMA.

  20. Length of stay in hospital

    Defined as the total number of completed days in hospital related to the initial admission for management of preterm birth.

    Time frame: Up to 44 weeks PMA

  21. Oxygen requirement at discharge to home

    Defined as the incidence of infants being discharged home on any form of oxygen therapy

    Time frame: Up to 44 weeks PMA

  22. Patent ductus arteriosus requiring medical or surgical therapy in first 72 hours

    Defined as the incidence of patent ductus arteriosus requiring medical or surgical therapy in first 72 hours

    Time frame: 72 hours of age.

  23. Meeting the protocol criteria for failure of non-invasive ventilation during the intervention period

    This is defined as the proportion of participants in the analysis set who met the criteria for requiring invasive ventilation (i.e. insertion of a Endotracheal Tube (ETT) within the first 72 hours after birth.

    Time frame: Up to the first 20 minutes after commencing respiratory support following birth.

07

Study locations

27 sites
08

References and documents

Publications

  • Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald EC, DeMauro SB. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019 Sep 15;200(6):751-759. doi: 10.1164/rccm.201812-2348OC. PubMed 30995069 ↗
  • Tingay DG, Galletta L, Owen LS, Kamlin O, Orsini F, Stewart D, Foglia E, Perkins E, Miedema M, Courtney SE, Simma B, Stelzl W, Katheria A, Lavizzari A, Roehr CC, Lista G, Bezette J, van Kaam AH, Kirpalani H, Davis PG; POLAR Trial Investigators. Positive end-expiratory pressure levels during resuscitation of preterm infants at birth (POLAR): study protocol for a randomised controlled trial. Pediatr Res. 2026 May 12. doi: 10.1038/s41390-026-04942-4. Online ahead of print. PubMed 42129370 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The de-identified data set collected for this analysis of the POLAR trial will be available six months after publication of the primary outcome. The study protocol, statistical analysis plan and consent forms will also be available. The data may be obtained from the Murdoch Children's Research Institute by emailing david.tingay@rch.org.au and mctc@mcri.edu.au.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 6 months after publication of primary outcome.

Access criteria: Prior to releasing any data the following are required: A Data Transfer Agreement must be signed between relevant parties. The MCRI Sponsorship Committee must review and approve your protocol and statistical analysis plan which must include and describe how the data will be used and analysed. An Authorship Agreement to be agreed to and signed between relevant parties. The Agreement must include details regarding appropriate recognition. Authorship may not be justifiable but some form of acknowledgement is requested. Agreement to cover any additional costs relating to the provision of the data. Evidence of ethics approval or waiver of approval, to be compliant with the data transfer agreement and ethics requirements at our end. Data will only be shared with a recognised research institution where the MCRI Sponsorship Committee has approved the proposed analysis plan.

Data sharing details ↗ · www.mcri.edu.au

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Nov 2026, 66 months after the start.

Of 28 interventional studies with no phase under Lung Injury, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 69. This study's planned 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2020
First posted
May 4, 2020
StartActual
May 4, 2021
Primary completionEst.
Nov 30, 2026
CompletionEst.
May 30, 2028
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04372953
Lead sponsor
Murdoch Childrens Research Institute
Responsible party
Sponsor
First posted
May 4, 2020
Start date
May 4, 2021
Primary completion
Nov 30, 2026 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Feb 19, 2026

Study contacts

David Tingay, MBBS FRACP
principal investigator · Royal Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion